Professional
Added to YB: 2024-11-22
Pitch date: 2024-11-22
VKTX [bullish]
Viking Therapeutics, Inc.
-30.67%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$4.4B
Pitch Price
$53.48
Price Target
109.00 (+194%)
Dividend
N/A
EV/EBITDA
-13.51
P/E
-18.45
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Viking Therapeutics (VKTX): B. Riley Issues Buy Rating with $109 Price Target
VKTX: B.Riley Buy, $109 PT. VK2735 GLP1/GIP agonist for obesity/T2D/MASH. Best-in-class Ph2 SQ & Ph1 oral data. EOP2 FDA meeting to clarify Ph3 trial, mfg capacity & positioning. Strong pipeline w/ amylin, SARM, THR-beta agents. Stock ~50% below 52wk high despite progress.
Read full article (1 min)